Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Levocetirizine
Drug ID BADD_D01272
Description Levocetirizine is a selective histamine H1 antagonist used to treat a variety of allergic symptoms.[A181748,A181790,L7694] It is the R enantiomer of [cetirizine].[L7694] Levocetirizine has greater affinity for the histamine H1 receptor than cetirizine.[L7694] Levocetirizine was granted FDA approval in 1995.[L7694]
Indications and Usage Levocetirizine is indicated for the relief of symptoms associated with allergic rhinitis (seasonal and perennial) in adults and children 6 years of age and older.
Marketing Status Prescription; OTC; Discontinued
ATC Code R06AE09
DrugBank ID DB06282
KEGG ID D07402
MeSH ID C472067
PubChem ID 1549000
TTD Drug ID D0M8PW
NDC Product Code Not Available
Synonyms levocetirizine | levocetrizine | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)- | (2-(4-((R)-p-chloro-alpha-phenylbenzyl)-1-piperazinyl)ethoxy)acetic acid | levocetirizine hydrochloride | Xusal | levocetirizine dihydrochloride | (2-(4-((R)-(4-chlorophenyl)phenylmethyl)piperazin-1-yl)ethoxy)acetic acid dihydrochloride | cetirizine (R)-form dihydrochloride | acetic acid, (2-(4-((R)-(4-chlorophenyl)phenylmethyl)-1-piperazinyl)ethoxy)-, dihydrochloride | Xyzal | UCB-28556
Chemical Information
Molecular Formula C21H25ClN2O3
CAS Registry Number 130018-77-8
SMILES C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
Not AvailableNot AvailableNot AvailableNot AvailableNot Available
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Blood immunoglobulin G increased13.06.05.0040.000585%Not Available
Blood lactate dehydrogenase increased13.04.02.0020.000585%
Blood pressure increased13.14.03.0050.000585%Not Available
Body temperature increased13.15.01.001--Not Available
Bradycardia02.03.02.0020.001169%Not Available
C-reactive protein increased13.09.01.0070.000585%Not Available
Cardiac failure02.05.01.0010.000153%
Cerebral infarction24.04.06.002; 17.08.01.0040.000585%Not Available
Chest discomfort22.02.08.001; 08.01.08.019; 02.02.02.0090.000877%Not Available
Cholestasis09.01.01.001--Not Available
Chromaturia20.02.01.0020.000585%
Chronic obstructive pulmonary disease22.03.01.0070.000585%Not Available
Constipation07.02.02.0010.001169%
Cough22.02.03.0010.001169%
Crying17.02.05.013; 19.04.02.002; 12.02.11.001; 08.01.03.0050.000585%Not Available
Cytomegalovirus infection11.05.01.0020.000585%
Deafness04.02.01.0010.000585%Not Available
Deafness neurosensory17.04.07.001; 04.02.01.0020.000585%Not Available
Death08.04.01.001--
Dehydration14.05.05.0010.000585%
Delirium19.13.02.0010.000585%
Dementia19.20.02.001; 17.03.01.0010.001462%Not Available
Depressed level of consciousness17.02.04.0020.001462%
Depression19.15.01.001--
Dermatitis23.03.04.0020.000585%Not Available
Diabetic ketoacidosis14.07.03.001; 05.07.03.0010.000585%Not Available
Diarrhoea07.02.01.001--
Disorientation19.13.01.002; 17.02.05.0150.000585%Not Available
Dizziness24.06.02.007; 17.02.05.003; 02.01.02.004--
Drug eruption08.01.06.015; 23.03.05.001; 10.01.01.0050.000585%Not Available
The 2th Page    First    Pre   2 3 4 5 6    Next   Last    Total 7 Pages